OA12778A - Pharmaceutical combination of COX-2 inhibitors andipiates. - Google Patents

Pharmaceutical combination of COX-2 inhibitors andipiates. Download PDF

Info

Publication number
OA12778A
OA12778A OA1200400220A OA1200400220A OA12778A OA 12778 A OA12778 A OA 12778A OA 1200400220 A OA1200400220 A OA 1200400220A OA 1200400220 A OA1200400220 A OA 1200400220A OA 12778 A OA12778 A OA 12778A
Authority
OA
OAPI
Prior art keywords
combination
daim
codeine
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
OA1200400220A
Other languages
English (en)
Inventor
Michael Christian Norris
Original Assignee
Adcock Ingram Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcock Ingram Ltd filed Critical Adcock Ingram Ltd
Publication of OA12778A publication Critical patent/OA12778A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200400220A 2002-02-19 2003-02-14 Pharmaceutical combination of COX-2 inhibitors andipiates. OA12778A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA200201395 2002-02-19

Publications (1)

Publication Number Publication Date
OA12778A true OA12778A (en) 2006-07-06

Family

ID=27758232

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400220A OA12778A (en) 2002-02-19 2003-02-14 Pharmaceutical combination of COX-2 inhibitors andipiates.

Country Status (20)

Country Link
US (1) US20050090517A1 (fr)
EP (2) EP1478366B1 (fr)
JP (1) JP2005519936A (fr)
CN (1) CN100418533C (fr)
AP (1) AP1862A (fr)
AT (2) ATE524186T1 (fr)
AU (1) AU2003208485B2 (fr)
CA (1) CA2476939C (fr)
CY (1) CY1108839T1 (fr)
DE (1) DE60325020D1 (fr)
DK (1) DK1478366T3 (fr)
EG (1) EG24845A (fr)
ES (2) ES2318113T3 (fr)
IL (2) IL163637A0 (fr)
NZ (1) NZ535500A (fr)
OA (1) OA12778A (fr)
PT (2) PT2050453E (fr)
SI (1) SI1478366T1 (fr)
WO (1) WO2003070251A1 (fr)
ZA (1) ZA200407485B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094832A1 (fr) * 2004-04-01 2005-10-13 Boehringer Ingelheim International Gmbh Compositions contenant du meloxicame
JP2008501655A (ja) * 2004-06-04 2008-01-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカム含有組成物
ITMI20060983A1 (it) * 2006-05-18 2007-11-19 Formevet S P A Composizioni farmaceutiche veterinarie per il trattamento del dolore e dell'inifiamazione
WO2007138466A2 (fr) * 2006-06-01 2007-12-06 Wockhardt Ltd Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
US20080026054A1 (en) * 2007-04-27 2008-01-31 Nectid Inc. Novel anelgesic combination
EP2177215A1 (fr) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
EP2311446A1 (fr) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprenant du Tramadol et du Célécoxib pour le traitement de la douleur
IT1398321B1 (it) * 2010-02-26 2013-02-22 Formevet Spa Ora Formevet Srl Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario
EP2392319A1 (fr) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Composition pharmaceutique contenant des co-cristaux de tramadol et d'un coxib
WO2015004505A1 (fr) * 2013-07-11 2015-01-15 More Pharma Corporation, S. De R.L. De C.V. Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire
WO2019130049A1 (fr) 2017-12-29 2019-07-04 Grünenthal GmbH Combinaison pharmaceutique comprenant du chlorhydrate de tramadol à libération prolongée et de l'étoricoxib à libération immédiate, et son utilisation pour le traitement de la douleur
US20210346328A1 (en) * 2018-09-21 2021-11-11 The Johns Hopkins University Compositions and methods for treating metabolic disorders
CN115300515A (zh) * 2022-08-11 2022-11-08 南京红地生物科技有限公司 一种含有美洛昔康和盐酸曲马多的长效注射液

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA845785B (en) * 1983-06-10 1985-03-27 Adcock Ingram Lab Ltd Pharmaceutical unit
ZA893422B (en) * 1988-02-24 1991-01-30 Adcock Ingram Lab Ltd Pharmaceutical composition
AU3990895A (en) * 1995-12-05 1997-06-27 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
FR2770131A1 (fr) * 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
RS50070B (sr) * 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
MXPA02010764A (es) * 2000-05-31 2003-03-10 Warner Lambert Co Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico.
RU2003100874A (ru) * 2000-06-13 2004-06-27 Вайс (Us) Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2

Also Published As

Publication number Publication date
AP2004003134A0 (en) 2004-09-30
IL163637A (en) 2010-11-30
ZA200407485B (en) 2005-12-28
ES2376500T3 (es) 2012-03-14
PT2050453E (pt) 2012-01-03
ATE415971T1 (de) 2008-12-15
EP2050453B1 (fr) 2011-09-14
CN1646133A (zh) 2005-07-27
CA2476939A1 (fr) 2003-08-28
PT1478366E (pt) 2009-03-10
AP1862A (en) 2008-07-07
EG24845A (en) 2010-10-21
EP1478366B1 (fr) 2008-12-03
CA2476939C (fr) 2012-08-28
WO2003070251A1 (fr) 2003-08-28
IL163637A0 (en) 2005-12-18
ATE524186T1 (de) 2011-09-15
DE60325020D1 (de) 2009-01-15
SI1478366T1 (sl) 2009-06-30
AU2003208485B2 (en) 2009-05-28
EP2050453A1 (fr) 2009-04-22
CN100418533C (zh) 2008-09-17
CY1108839T1 (el) 2014-07-02
DK1478366T3 (da) 2009-03-30
ES2318113T3 (es) 2009-05-01
EP1478366A1 (fr) 2004-11-24
NZ535500A (en) 2006-09-29
JP2005519936A (ja) 2005-07-07
AU2003208485A1 (en) 2003-09-09
US20050090517A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
OA12778A (en) Pharmaceutical combination of COX-2 inhibitors andipiates.
Lázaro-Ibáñez et al. Participation of the nitric oxide–cyclic GMP–ATP-sensitive K+ channel pathway in the antinociceptive action of ketorolac
Löscher Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy
Keyhanfar et al. Evaluation of antinociceptive effect of pregabalin in mice and its combination with tramadol using tail flick test
Ward et al. Paracetamol revisited: a review of the pharmacokinetics and pharmacodynamics
Gregoretti et al. Analgo-sedation of patients with burns outside the operating room
Abbott et al. Phenacetin, acetaminophen and dipyrone: analgesic and rewarding effects
Slivicki et al. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro
EP3057583A2 (fr) Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent analgésique
Miranda et al. Spinal synergy between nonselective cyclooxygenase inhibitors and morphine antinociception in mice
Rasmussen Treatment of elevated intracranial pressure with indomethacin: friend or foe?
Granados-Soto et al. A review of the pharmacokinetic and pharmacodynamic factors in the potentiation of the antinociceptive effect of nonsteroidal anti-inflammatory drugs by caffeine
Moreno-Rocha et al. Antinociceptive effects of tramadol in co-administration with metamizol after single and repeated administrations in rats
Brown-Croyts et al. Phenobarbital pre-treatment prevents kainic acid-induced impairments in acquisition learning
BR0317950A (pt) Inibidores de quinurrenina 3-hidroxilase para o tratamento de diabetes por aumento do número de ilhotas de células de langerhans
Kelkar et al. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Luo et al. Effects of three different Ca2+ pump ATPase inhibitors on evoked contractions in rabbit aorta and activities of Ca2+ pump ATPases in porcine aorta
Saini et al. Fixed drug eruptions: causing drugs, pattern of distribution and causality assessment in a leading tertiary care hospital
Fruhwald et al. Differential reversal of drug-induced small bowel paralysis by cerulein and neostigmine
Mitchell et al. Antihypernociceptive synergy between ibuprofen, paracetamol and codeine in rats
Kardani et al. Cycloserine-induced Acute Psychiatric Episode with XDRTB treatment in an Indian Patient-A Report.
Putri et al. Mechanism of Action, Cellular Targets and Clinical Importance of Analgesic Therapy in Postoperative Pediatric Patients: A Brief Observation
Déciga-Campos et al. Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception
Jesuthasan et al. Pain Analgesic Developments in the Genomic Era
Mogole et al. The management of muscle pain